Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial

Overview of attention for article published in BMC Medicine, March 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 11 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 1 outlets.

Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer | 2 Minute Medicine

2 Minute Medicine , 15 Mar 2023

1. In this phase II randomized clinical trial, treatment of patients with locally advanced esophageal squamous cell carcinoma (ES…

2 Minute Medicine Rewind March 13, 2023 | 2 Minute Medicine

2 Minute Medicine , 13 Mar 2023

Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.